Si ça continue comme ça le gaz naturel va être gratuit!
Opinion & investing ideas
samedi 22 août 2009
vendredi 21 août 2009
Ce matin avec Jeff sur Radiopirate.com xm172
GXF.nyse le nouveau ETF global x nordic
CKGT.otcbb Kangtai cactus
jeudi 20 août 2009
Grosse position
J'ai embarqué beaucoup de cash dans Cameco aujourd'hui à 31$ et des poussières.......Laissons le tout "mijoter" un peu.!
mercredi 19 août 2009
made in china
Audi's world's biggest assembly plant with a maximum annual capacity of 200,000 vehicles is to be inaugurated in September in the city of Changchun of northeastern China's Jilin province, lifting the German carmaker's Chinese capacity to 400,000, FAW-Audi Sales Division vice president Zhang Xiaojun told the Oriental Morning Post Sunday. The ¥1 billion factory will mainly produce Audi's A4L and the Q5 models. The brand sold 79,390 vehicles in China during the year throughly July, up 14.9% from a year earlier, Zhang said. BMW got the go-ahead earlier this month to double the capacity of its existing Chinese plant to 120,000 vehicles a year.
QUIX.nasdaq
En tant que boursicoteur depuis près de 14 ans maintenant, il y a un phénomène bizarre qui
dure depuis le début. Il y a des compagnies qui m'ont toujours intéressé mais où je n'ai jamais
mis une cenne! Quixote en est
Imaginez! Il y a seulement 9.3M
actions sur le marché avec un float de
6.5M...Regardez le genre de business et dites-moi que ce n'est pas
interessant pour un moyen terme.
Je me dit ça depuis des lunes! Mon flair m'a bien guider avec celle-ci.....mais l'à à 2.30$ .....ça me fatigue plus que jamais.
QUIX.nasdaq résultats du quatrième trimestre et fin d'année fiscale ce jeudi 20 août 10ham
http://www.quixotecorp.com/mardi 18 août 2009
Sucre (2)
The investment seeks to replicate, net of expenses, the Dow Jones-AIG Sugar Total Return Sub-Index. The index is intended to reflect the returns that are potentially available through an unleveraged investment in sugar futures contracts as well as the rate of interest that could be earned on cash collateral invested in specified Treasury Bills.
IPATH DJ-AIG SUGAR /SGG.nyse
http://www.latimes.com/business/la-fi-sugar14-2009aug14,0,4601168.story
Sucre
1.) Les Indiens consoment plus de 22 millionsde tonnes de sucre par année ...les numéro 1 au monde.
En comparaison au Canada nous sommes sous les 1.8 millions
de tonnes.
2.) Normalement les Indiens sont autosuffisants mais là ils sont
"short" pour cette année de 8 millions de tonnes à cause de
la température.....les réserves sont vides et les prix
sont à la hausse....voir le "28 year high"
http://www.financialpost.com/story.html?id=1877577
3.) Le Brésil qui peut fournir à lui seul l'Inde est passé en mode "vert".
Les "clowns" font du fuel avec la canne à sucre......
RSI.un.to à surveiller
lundi 17 août 2009
2009-08-17 02:00 ET - News Release
Quand une compagnie annonce une nouvelle à 2 heures du matin c'est rare quelle est positive....
QUEBEC CITY, Aug. 17 /CNW Telbec/ - Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with Æterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.
Study Z-033
The first multi-center efficacy trial Z-033 was conducted in 53 sites in the United States and Canada, with 8 additional sites in Europe. The study involved 667 patients under the supervision of lead investigator, Herbert Lepor, M.D., Professor and Chairman, Department of Urology, at NYU School of Medicine, New York. Patients entered a 1- to 4-week screening period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients were then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients were administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 (for treatment Arm A, those in Arm B received IM injection at week 0, 2 and 26 followed by placebo at Week 28). Patients in treatment Arm C received placebo injections at Week 0, 2, 26 and 28. All patients were followed up to Week 52.
The study Z-033 demonstrated no clear differences in overall efficacy with all 3 groups showing an improvement in IPSS of approximately 4 points that was maintained throughout the 52 weeks. There was a slight advantage in favor of the main active treatment arm (Arm A) up to Week 46 of the follow-up, which was no longer demonstrated at Week 52. These differences did not achieve statistical significance. Furthermore, a favorable trend on the IPSS, as compared to placebo, was seen in a sub-group of patients with large prostate glands (greater than 50 cm3) on entry to the study.
Tolerability of cetrorelix in study Z-033 was very good, as evidenced by the absence of major differences to placebo with regard to both clinical adverse events or changes in laboratory parameters. The most frequently reported adverse experiences included hot flushes, nasopharyngitis, injection site pain, and headache, which is what was seen in the safety study Z-041. In particular, the incidence of hot flushes was lower than was seen in study Z-041 (see below), and they were also reported by patients randomized to placebo.
Study Z-041
In the safety study Z-041, all patients received cetrorelix by intra-muscular (IM) injection at Weeks 0 and 2, and were followed up to Week 26. The primary endpoint was the incidence of possibly drug-related adverse events; efficacy parameters were evaluated as secondary endpoints. The study was conducted in 68 sites in the United States and Canada.
Cetrorelix was generally well tolerated. Adverse events were mostly mild and transient in intensity. Serious adverse events occurred in 12 patients, but none of these was assessed as possibly drug-related. The most frequently reported adverse experiences included hot flushes, nasopharyngitis, injections site pain, and headache. Hot flushes were reported by 49 patients and were mild and of short duration in the majority of patients. Only one patient experienced a severe episode. A questionnaire was used to assess the local tolerance of the IM injection and affirmed the acceptability of this route of administration.
Efficacy was assessed using the IPSS which showed an improvement from a mean score of 21.2 at baseline to 15.6 at Week 26. In 63% of the patients, the improvement was by at least 3 points. Notably, the 46% of patients who had received previous treatment for BPH showed an important mean improvement of 5 points, which is only slightly less than the 6 point improvement seen in treatment-naïve patients. Maximum uroflow improved by 25%, from 10.3 to 12.5 ml/sec, and also the mean uroflow showed similar improvement.
Juergen Engel, Ph.D., Æterna Zentaris President and CEO stated, "Although the data received for the open-label safety study Z-041 with a nearly 6 point reduction in IPSS are in line with what we had observed in our Phase 2 program, we are disappointed by the failure to achieve the primary endpoint in the efficacy study Z-033. We remain committed to the ongoing Phase 3 program with cetrorelix in BPH and are working towards receiving the results of the second pivotal efficacy study Z-036 in November."
Study Z-033
The first multi-center efficacy trial Z-033 was conducted in 53 sites in the United States and Canada, with 8 additional sites in Europe. The study involved 667 patients under the supervision of lead investigator, Herbert Lepor, M.D., Professor and Chairman, Department of Urology, at NYU School of Medicine, New York. Patients entered a 1- to 4-week screening period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients were then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients were administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 (for treatment Arm A, those in Arm B received IM injection at week 0, 2 and 26 followed by placebo at Week 28). Patients in treatment Arm C received placebo injections at Week 0, 2, 26 and 28. All patients were followed up to Week 52.
The study Z-033 demonstrated no clear differences in overall efficacy with all 3 groups showing an improvement in IPSS of approximately 4 points that was maintained throughout the 52 weeks. There was a slight advantage in favor of the main active treatment arm (Arm A) up to Week 46 of the follow-up, which was no longer demonstrated at Week 52. These differences did not achieve statistical significance. Furthermore, a favorable trend on the IPSS, as compared to placebo, was seen in a sub-group of patients with large prostate glands (greater than 50 cm3) on entry to the study.
Tolerability of cetrorelix in study Z-033 was very good, as evidenced by the absence of major differences to placebo with regard to both clinical adverse events or changes in laboratory parameters. The most frequently reported adverse experiences included hot flushes, nasopharyngitis, injection site pain, and headache, which is what was seen in the safety study Z-041. In particular, the incidence of hot flushes was lower than was seen in study Z-041 (see below), and they were also reported by patients randomized to placebo.
Study Z-041
In the safety study Z-041, all patients received cetrorelix by intra-muscular (IM) injection at Weeks 0 and 2, and were followed up to Week 26. The primary endpoint was the incidence of possibly drug-related adverse events; efficacy parameters were evaluated as secondary endpoints. The study was conducted in 68 sites in the United States and Canada.
Cetrorelix was generally well tolerated. Adverse events were mostly mild and transient in intensity. Serious adverse events occurred in 12 patients, but none of these was assessed as possibly drug-related. The most frequently reported adverse experiences included hot flushes, nasopharyngitis, injections site pain, and headache. Hot flushes were reported by 49 patients and were mild and of short duration in the majority of patients. Only one patient experienced a severe episode. A questionnaire was used to assess the local tolerance of the IM injection and affirmed the acceptability of this route of administration.
Efficacy was assessed using the IPSS which showed an improvement from a mean score of 21.2 at baseline to 15.6 at Week 26. In 63% of the patients, the improvement was by at least 3 points. Notably, the 46% of patients who had received previous treatment for BPH showed an important mean improvement of 5 points, which is only slightly less than the 6 point improvement seen in treatment-naïve patients. Maximum uroflow improved by 25%, from 10.3 to 12.5 ml/sec, and also the mean uroflow showed similar improvement.
Juergen Engel, Ph.D., Æterna Zentaris President and CEO stated, "Although the data received for the open-label safety study Z-041 with a nearly 6 point reduction in IPSS are in line with what we had observed in our Phase 2 program, we are disappointed by the failure to achieve the primary endpoint in the efficacy study Z-033. We remain committed to the ongoing Phase 3 program with cetrorelix in BPH and are working towards receiving the results of the second pivotal efficacy study Z-036 in November."
Grignotage
The Inventure Group Inc. (SNAK.nasdaq)Voici un "low float" à surveiller.
17 M actions....11 M float!
Les derniers résultats sont bons et
semble vouloir faire des alliances
avec des marques connues.
En liste dernièrement....
Jamba and The Inventure Group Partner to Develop An Innovative, Better-for-You Line of Make-At-Home Frozen Smoothie Kits
The Snack Division contributed net revenues of $21.7 million, up 13.5% versus the same period last year. The company attributed the increase in net revenue in the Snack Division to higher year-over-year product sales across the majority of its products including Boulder Canyon(tm) Natural Foods (up 25.7 %), T.G.I. Friday's(r)(up 3.5 %), BURGER KING(tm) (up 45.9 %) and Private Label (up 155 %). These increases were partially offset by a year-over-year decline in sales at the Poore Brothers(r) brand.
Inscription à :
Articles (Atom)